ibandronic acid clonmel 150mg film-coated tablets
clonmel healthcare limited waterford road, clonmel, co. tipperary e91 d768, ireland - ibandronic acid - film-coated tablet - ibandronic acid 150 mg - drugs for treatment of bone diseases
ibandronic acid mylan 150 mg film-coated tablets
neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - ibandronic acid - film-coated tablet - ibandronic acid 150 mg - drugs for treatment of bone diseases
ibandronic acid 150mg tablets
arrow generics ltd - ibandronic sodium monohydrate - tablet - 150mg
ibandronic acid 6 mg concentrate for solution for infusion
noridem enterprises limited - ibandronate sodium monohydrate - concentrate for solution for infusion - 6 milligram(s) - bisphosphonates; ibandronic acid
bondronat for infusion 1 mgml
dksh singapore pte. ltd. - ibandronic acid, monosodium salt, monohydrate eqv. to ibandronic acid - injection - 1mg/ml - ibandronic acid, monosodium salt, monohydrate eqv. to ibandronic acid 1mg/ml
ibandronate sodium- ibandronate sodium injection, solution
heritage pharmaceuticals inc. - ibandronate sodium (unii: j12u072ql0) (ibandronic acid - unii:umd7g2653w) - ibandronic acid 3 mg in 3 ml - ibandronate sodium injection is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, ibandronate increases bone mineral density (bmd) and reduces the incidence of vertebral fractures [see clinical studies(14)]. the safety and effectiveness of ibandronate for the treatment of osteoporosis are based on clinical data of one year duration. the optimal duration of use has not been determined. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. ibandronate is contraindicated in patients with the following conditions: - hypocalcemia [see warnings and precautions (5.1)] - known hypersensitivity to ibandronate sodium injection or to any of its excipients. cases of anaphylaxis, including fatal event
bonviva
roche diagnostics gmbh - ibandronic acid - solution for i/v injection - 1mg/ml
ibandronic acid 50mg tablets
zentiva - ibandronic sodium monohydrate - tablet - 50mg
ibandronic acid 50mg tablets
alliance healthcare (distribution - ibandronic sodium monohydrate - tablet - 50mg
ibandronic acid 50mg tablets
a a h pharmaceuticals ltd - ibandronic sodium monohydrate - tablet - 50mg